DBV Technologies Reports First Quarter 2025 Financial Results
Rhea-AI Summary
DBV Technologies reported its Q1 2025 financial results, showing a decrease in cash position to $13.0 million as of March 31, 2025, down from $32.5 million at the end of 2024. The company's net loss was $27.1 million, or $(0.26) per share, slightly improved from $27.3 million in Q1 2024.
Key financial highlights include:
- Operating expenses decreased to $27.4 million from $30.0 million year-over-year
- Research & Development costs remained stable at $21.5 million
- Operating income declined to $0.8 million from $1.4 million
Notably, the company secured a significant financing of up to $306.9 million on March 27, 2025, with initial proceeds of $125.5 million received in April 2025. This funding is intended to advance the Viaskin Peanut Patch through BLA submission and potential U.S. commercial launch. The company projects its current cash position will fund operations into June 2026.
Positive
- Secured significant financing of $306.9M in March 2025, including $125.5M received in April
- Operating expenses decreased by $2.6M compared to Q1 2024
- Slight improvement in net loss per share from $(0.28) to $(0.26)
- Cash runway extended into June 2026 with new financing
Negative
- Cash position severely declined to $13M from $32.5M in Q4 2024
- Significant cash burn of $19.7M in operating activities in Q1
- Operating income decreased to $0.8M from $1.4M YoY
- Continued operating losses with net loss of $27.1M in Q1
- Shareholders' equity dramatically decreased to $2.9M from $27.4M in Q4 2024
News Market Reaction 1 Alert
On the day this news was published, DBVT declined 4.44%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Châtillon, France, April 30, 2025
DBV Technologies Reports First Quarter 2025 Financial Results
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025.
Financial Highlights for the First Quarter Ended March 31, 2025
The Company’s interim condensed consolidated financial statements for the three months ended March 31, 2025, are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).
Cash and Cash Equivalents
Our Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
Cash and cash equivalents amounted to
On March 27, 2025, the company announced a financing of up to
The Company has incurred operating losses and negative cash flows from operations since inception. The Company does not generate product revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.
These condensed consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company was unable to continue as a going concern.
| In millions of USD (unaudited) | U.S. GAAP | |
| three months ended March 31, | ||
| 2025 | 2024 | |
| Net cash & cash equivalents at the beginning of the period | 32.5 | 141.4 |
| Net cash flow used in operating activities | (19.7) | (34.7) |
| Net cash flow provided by / (used in) investing activities | (0.4) | (2.1) |
| Net cash flow provided by / (used in) financing activities | — | (0.1) |
| Effect of exchange rate changes on cash & cash equivalents | 0.5 | (3.0) |
| Net cash & cash equivalents at the end of the period | 13.0 | 101.5 |
Operating Income
Operating income amounted to
| In millions of USD (unaudited) | U.S. GAAP | |
| three months ended March 31, | ||
| 2025 | 2024 | |
| Research tax credits | 0.8 | 1.4 |
| Other operating income | — | — |
| Operating income | 0.8 | 1.4 |
Operating Expenses
Operating expenses amounted to
| In millions of USD (unaudited) | U.S. GAAP | |
| three months ended March 31, | ||
| 2025 | 2024 | |
| Research & Development | (21.5) | (21.4) |
| Sales & Marketing | (0.3) | (0.8) |
| General & Administrative | (5.6) | (7.8) |
| Operating expenses | (27.4) | (30.0) |
Net Loss and Net Loss Per Share
The Company recorded a net loss of
On a per share basis, net loss (based on the weighted average number of shares outstanding over the period) was
| U.S. GAAP | ||
| three months ended March 31, | ||
| 2025 | 2024 | |
| Net (loss) (in millions of USD) | (27.1) | (27.3) |
| Basic / diluted net (loss) per share (USD/share) | (0.26) | (0.28) |
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
| In millions of USD | U.S. GAAP | |
| March 31, 2025 | December 31, 2024 | |
| Assets | 50.6 | 65.7 |
| of which cash & cash equivalents | 13.0 | 32.5 |
| Liabilities | 47.7 | 38.3 |
| Shareholders’ equity | 2.9 | 27.4 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| In millions of USD | U.S. GAAP | |
| three months ended March 31, | ||
| 2025 | 2024 | |
| Operating income | 0.8 | 1.4 |
| Research & Development | (21.5) | (21.4) |
| Sales & Marketing | (0.3) | (0.8) |
| General & Administrative | (5.6) | (7.8) |
| Operating expenses | (27.4) | (30.0) |
| Financial income/(expenses) | (0.5) | 1.3 |
| Income tax | — | — |
| Net loss | (27.1) | (27.3) |
| Basic/diluted net loss per share attributable to shareholders | (0.26) | (0.28) |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| In millions of USD | U.S. GAAP | |
| three months ended March 31, | ||
| 2025 | 2024 | |
| Net cash flows (used) in operating activities | (19.7) | (34.7) |
| Net cash flows (used) in investing activities | (0.4) | (2.1) |
| Net cash flows (used) in financing activities | — | (0.1) |
| Effect of exchange rate changes on cash & cash equivalents (U.S. GAAP presentation) | 0.5 | (3.0) |
| Net increase / (decrease) in cash & cash equivalents | (19.5) | (39.8) |
| Net cash & cash equivalents at the beginning of the period | 32.5 | 141.4 |
| Net cash & cash equivalents at the end of the period | 13.0 | 101.5 |
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding DBV’s financial condition, forecast of its cash runway, the therapeutic potential of Viaskin® Peanut patch and EPIT™, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
Viaskin is a registered trademark and EPIT is a trademark of DBV Technologies.
DBV Investor Relations Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
DBV Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com
Attachment
FAQ
How much cash does DBVT have as of March 31, 2025?
What is DBVT's Q1 2025 net loss per share?
How much financing did DBVT secure in March 2025?
How long will DBVT's current cash reserves last?
What were DBVT's operating expenses in Q1 2025?
What is the purpose of DBVT's recent financing?
